Trial Search Results

68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment

The purpose of this research study is to see if recurrent prostate cancer can be identified using a special procedure called a positron emission tomography (PET) scan. PET/CT is used to describe information regarding the function, as well as location and size of a tumor.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Andrei Iagaru

Stanford Investigator(s):

Intervention(s):

  • Procedure: Computed Tomography (CT) scan
  • Drug: 68Ga-PSMA-11
  • Procedure: Positron Emission Tomography (PET)

Phase:

Phase 2/Phase 3

Eligibility


Inclusion Criteria:

   - Histopathological proven prostate adenocarcinoma

   - Rising prostate-specific antigen (PSA) after definitive therapy with prostatectomy or
   radiation therapy (external beam or brachytherapy)

      - Post radical prostatectomy (RP) - American Urology Association (AUA)
      recommendation

         - PSA greater than 0.2 ng/mL measured 6 to 13 weeks after RP

         - Confirmatory persistent PSA greater than 0.2 ng/mL (total of two PSA
         measurements greater than 0.2 ng/mL)

      - Post-radiation therapy -American Society for Radiation Oncology (ASTRO)-Phoenix
      consensus definition

         - A rise of PSA measurement of 2 or more ng/mL over the nadir

   - Karnofsky performance status of ≥ 50 (or Eastern Cooperative Oncology Group [ECOG] /
   World Health Organization [WHO] equivalent)

   - Able to provide written consent

Exclusion Criteria:

   - Investigational therapy for prostate cancer.

   - Unable to lie flat, still or tolerate a positron emission tomograpy (PET) scan.

   - Prior history of any other malignancy within the last 2 years, other than skin basal
   cell or cutaneous superficial squamous cell carcinoma that has not metastasized and
   superficial bladder cancer.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Male

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
David Marcellus
650-723-4547
Not Recruiting